The Inconvenient Truth Behind RFK Jr.’s Vaccine Business Model Claim

 When Robert F. Kennedy Jr. said in a September 17, 2020 interview, later removed by YouTube for "medical misinformation," that pharmaceutical companies make roughly $60 billion a year on vaccines but $500 billion selling remedies for the injuries they cause, he framed it as a perverse but highly profitable business plan: "You make people sick, and then you sell them the lifetime cure." At first glance, it sounds like classic conspiracy rhetoric. But peeling back the layers reveals an uncomfortable reality about incentives, liability shields, and the sheer scale of the modern pharmaceutical industry that deserves honest scrutiny rather than outright dismissal.

Let's start with the numbers. Global vaccine revenues were indeed in the tens of billions annually even before the COVID-19 surge pushed them higher (estimates around $50–90 billion in recent years, with $60 billion a reasonable ballpark for the 2020 period). The industry has grown rapidly due to government contracts, mandatory schedules in many countries, and public health campaigns. On the other side, the U.S. National Vaccine Injury Compensation Program (VICP), the no-fault system shielding manufacturers from most lawsuits, has paid out over $5 billion since 1988 across thousands of claims. While that is not $500 billion per year, RFK Jr.'s broader point taps into a larger ecosystem: lifelong management of chronic conditions (autoimmune issues, neurological problems, allergies) that some attribute to vaccine side effects, plus the massive markets for treatments, therapies, and pharmaceuticals that address them. The pharmaceutical industry as a whole generates well over a trillion dollars annually. If even a fraction of chronic illness burden is linked to vaccines, the downstream profits are enormous.

The real "inconvenient truth" is not that every vaccine is a deliberate harm vector, but that the current system creates misaligned incentives. Vaccine manufacturers enjoy extraordinary legal protections under the 1986 National Childhood Vaccine Injury Act. They cannot be sued directly in civil court for most injuries; claims go through the VICP, funded by a small excise tax on vaccines. This no-fault system was designed to ensure vaccine supply and encourage development after lawsuits threatened the industry in the 1980s. It has compensated thousands of people, often through settlements without admitting causation. Proponents say it balances safety with access. Critics like RFK Jr. argue it removes the normal market pressure that would force companies to prioritise safety above all else, because the downside risk is socialised while upside profits remain privatised.

Add to this the revolving door between regulators (FDA, CDC) and industry, heavy reliance on vaccine schedules for revenue stability, and the difficulty of independent long-term safety studies on cumulative effects of multiple vaccines. Serious adverse events are acknowledged as rare by health authorities, but the definition of "rare" and the reporting systems (like VAERS, which is passive and under-reports according to some studies) leave room for legitimate debate. When billions are at stake and governments mandate products, questioning the profit-safety balance is not fringe, it's responsible oversight.

RFK Jr.'s phrasing is provocative, and the exact $500 billion figure is likely an extrapolation that includes broader chronic disease treatment markets rather than direct "vaccine injury cures." But the core observation, that creating a lifelong customer through medical intervention is better business than one-time prevention, echoes patterns seen across pharma: statins for lifelong cholesterol management, insulin for diabetes, antidepressants for mental health. Vaccines fit neatly into a wellness-to-illness pipeline if side effects are under-acknowledged or downplayed. The removal of the interview by YouTube in 2020 exemplified the institutional resistance to this line of inquiry during the height of COVID panic, where any dissent was labelled "misinformation." That heavy-handed censorship only fuelled suspicion that inconvenient questions were being suppressed.

RFK Jr.'s larger point forces us to confront whether the current model optimises for health or for perpetual pharmaceutical dependence. When industry revenues soar while chronic illness rates rise in vaccinated populations, and when legal shields and regulatory capture limit accountability, the business plan critique lands with uncomfortable force.